Argos Therapeutics expands global patent protection (Argos Therapeutics) - Sep 6, 2012 - Allowed claims cover use of AGS-009 to treat SLE, IDDM, or psoriasis; Patent issuing from application is expected to expire in 2026
Anticipated patent expiry • Patent • Immunology • Lupus
|
|
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced it was recently granted two patents and one patent allowance from the United States Patent and Trademark Office (USPTO) and one patent allowance from the European Patent Office (EPO). These new patents and allowed patent applications cover compositions of matter and methods of use related to Argos´ proprietary immunotherapy technologies.
*** *** ***
The U.S. notice of allowance is for U.S. Patent Application 13/252,335, entitled ”Anti-interferon alpha monoclonal antibodies and methods for use,“ which is related to AGS-009. The allowed claims cover the use of certain monoclonal antibodies to treat SLE, IDDM, or psoriasis. The patent issuing from this application is expected to expire in 2026. ...
(IR8)
|